 MONT-SAINT-GUIBERT, Belgium--BUSINESS WIRE--Regulatory News: Celyad Oncology SA Brussels:CYAD Paris:CYAD NASDAQ:CYAD Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced updates from the companys shRNA-based anti-B cell maturation antigen BCMA allogeneic CAR T candidate, CYAD-211, and autologous NKG2D receptor-based CAR T candidates, CYAD-01 and 